Xcision Medical Systems

Xcision Medical Systems develops the GammaPod, the first and only FDA-cleared stereotactic radiotherapy system specifically designed for early-stage breast cancer treatment. The company focuses exclusively on advancing breast cancer care through innovative radiation oncology technology. The GammaPod platform enables significantly shortened treatment courses (5 days or fewer) compared to conventional external beam radiation therapy (4–6 weeks), delivering non-invasive, non-surgical treatment with rapid recovery. The system uses advanced imaging and radiation delivery to provide patient-friendly, protective care for eligible early-stage breast cancer patients. Xcision is headquartered in Columbia, Maryland, and actively participates in major oncology conferences (ESTRO, Arab Health) and industry initiatives to modernize radiation oncology reimbursement. The company holds FDA clearance for the GammaPod and is engaged in clinical and commercial partnerships to expand access to this specialized breast cancer treatment modality.